Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
ALANINE ARGININE ASPARTIC ACID CYSTEINE L-GLUTAMIC ACID AMINOACETIC ACID HISTIDINE ISOLEUCINE LEUCINE L-LYSINE L-METHIONINE PHENYLALANINE PROLINE SERINE THREONINE TRYPTOPHAN, L- TYROSINE VALINE
Fresenius Kabi Limited
ALANINE ARGININE ASPARTIC ACID CYSTEINE L-GLUTAMIC ACID AMINOACETIC ACID HISTIDINE ISOLEUCINE LEUCINE L-LYSINE L-METHI
1000ml Millilitre
Solution for Infusion
Withdrawn
2009-05-01
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0566/024/002 Case No: 2054816 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to FRESENIUS KABI LIMITED CESTRIAN COURT, EASTGATE WAY, MANOR PARK, RUNCORN, CHESHIRE WA7 1NT, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product VAMIN 18 ELECTROLYTE - FREE SOLUTION FOR INFUSION, 1000ML. The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 10/03/2009 until 20/06/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 10/03/2009_ _CRN 2054816_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vamin 18 Electrolyte-Free Solution for Infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1000 ml contains: _Product Particulars_ For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion. A clear, colourless to slightly yellow solution of amino acids. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the prophylaxis or therapeutic treatment of protein depletion, where sufficient enteral nutrition is impossible or impracticable. It is particularly suited to meetmoderately increased requirements for nitrogen in patients in Soma hati kamili